Skip to content

Don’t invest unless you’re prepared to lose all the money you invest. You are unlikely to be protected if something goes wrong. Take 2 mins to learn more

Year: 2021

Calculus invests in eConsult

eConsult Health is the leading online consultation provider to the NHS for primary care With considerable growth over the last year the platform is now live in over 3,200 NHS GP practices and gives millions of patients access to their own GP online. The funding round will be used to accelerate growth in primary care … Continued

Naomi Watts to headline new film produced by Maven Screen Media

Naomi Watts is set to headline “Infinite Storm,” the highly anticipated film from Polish director Malgorzata Szumowska. “Infinite Storm” is being produced by Maven Screen Media’s Celine Rattray, Trudie Styler and Jenny Halper with Naomi Watts for JamTart Productions, as well as Peter and Michael Sobiloff. Calculus invested in Maven Screen Media in August 2020. Specifically, Maven … Continued

Surrey trust pilots the NHS’ first-of-its-kind demand-led rostering solution with Rotageek

Surrey-based Ashford and St Peter’s Hospitals NHS Foundation Trust, one of the UK’s foremost Trusts, is piloting a demand-led rostering solution with Rotageek and Locum’s Nest, who create software connecting healthcare professionals to flexible work. Together they will test the NHS’ first-of-its-kind demand-led rostering. The solution links scheduling and locums in an integrated network that … Continued

An Investment Outlook: Looking forward to 2021

Richard Moore – Co head of Investments Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. 2020 impacted businesses both large and small. Covid-19 and government mandated lockdowns created a very uncertain economic outlook and … Continued

Oxford BioTherapeutics establishes research collaboration with global cell therapy leader, Kite

Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies and Kite, a Gilead Company, have announced that they have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications. Through this collaboration, OBT will validate five … Continued

Arecor’s partner Inhibrx to license first formulation

Arecor has announced that partner Inhibrx Inc. is to license a novel enhanced formulation of its proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat™. This is the first license under a multi-product development agreement between two companies with the new formulation developed using Arestat, Arecor’s patented reformulation platform. INBRX-101 is a treatment for … Continued

Important Information

The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund or Calculus VCT.

An investment into the Calculus EIS Fund of Calculus VCT may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.

When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS or VCT unless you can afford to lose some or all of your capital.

An EIS or VCT investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.

The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.

I have read and understood this important information

Important Information

The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund or Calculus VCT.

An investment into the Calculus EIS Fund of Calculus VCT may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.

When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS or VCT unless you can afford to lose some or all of your capital.

An EIS or VCT investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.

The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.

I have read and understood this important information